Research at NIBRT

Our research programmes cover all aspects of the biopharma manufacturing process

NIBRT Research

NIBRT Research is a world leader in developing innovative technologies that advance biopharmaceutical manufacturing and a resource for the global biopharmaceutical industry. Inspired by the manufacturing challenges facing the industry, NIBRT Research makes transformative discoveries across multidisciplinary areas such as analytical science, cell and genetic engineering, informatics, and bioprocess engineering.These discoveries are utilized to advance the state-of-the-art in their fields and revolutionize the manufacturing of recombinant proteins, vaccines and cell and gene therapies.

NIBRT Research engages postdoctoral scientists and graduate students in leading edge biopharmaceutical research, helping to inform and inspire the next generation of research leaders in industry and academia.

NIBRT Research is comprised of eminent scientists supported by world-class facilities and dedicated support teams who actively pursue productive collaborations with academic and industrial scientists in Ireland and throughout the world. Thus, NIBRT will deliver outstanding biopharmaceutical manufacturing research built on effective collaboration and world-leading innovation.

NIBRT Science Advisory Board:

Dr Robert Baffi, Prof Martin Clynes, Prof. Charles Cooney,  Dr Matt Croughan, Prof Gavin Davey, Prof Alan Dickson, Prof. Brian Glennon, Dr Brendan Hughes, Prof Barry Karger, Barry McCarthy, Prof. Pauline Rudd

The NIBRT Research Team

Our research team cover all aspects of the biopharma manufacturing process

Elizabeth Topp

Chief Scientific Officer

Dr. Topp holds a bachelor’s degree in chemical engineering (BChE) from the University of Delaware, a master’s degree in engineering (ME) from the University of Pennsylvania and a PhD in pharmaceutics from the University of Michigan.

View Profile

Michael Butler

Principal Investigator

Michael Butler is Principal Investigator the National Institute of Bioprocessing Research & Training (NIBRT), Adjunct Full Professor at University College Dublin (UCD) and Distinguished Professor Emeritus of the University of Manitoba, Canada.

View Profile

Jonathan Bones

Prinicipal Investigator

Dr. Bones obtained his BSc in Analytical Science (Chemistry) and PhD in Analytical Chemistry from Dublin City University (DCU) under the guidance of Prof. Brett Paull.

View Profile

Niall Barron

Principal Investigator

Niall Barron was appointed NIBRT Principal Investigator and Professor of Biochemical Engineering in the School of Chemical and Bioprocess Engineering in UCD in 2017.

View Profile

Colin Clarke

Principal Investigator

Dr. Clarke graduated with a PhD in Bioinformatics from Cranfield University, UK, and specialises in the application of multivariate statistics and machine learning algorithms to high dimensional data.

View Profile

Radka Fahey

Starting Investigator

Dr Fahey joined the GlycoScience group in May 2005 as a Research Assistant and defended her PhD at the Institute of Chemical Technology Prague in November 2007.

View Profile

Steven Ferguson

Principal Investigator

Steven Ferguson is a Principal Investigator in the National Institute for Bioprocess Research and Training focused on the development of downstream processing and advanced manufacturing technologies, for separation and purification of biopharmaceuticals and advanced therapeutic medicinal products.

View Profile

Cell and Gene Therapy and Vaccine Manufacturing Forum

The Cell and Gene Therapy and Vaccine Manufacturing Forum (CGTV Forum) was established in late 2018 in order to address the opportunity for Ireland to capitalise on the burgeoning therapeutic and commercial interest in cell and gene therapies (and more recently novel vaccines) – and in particular to replicate the success seen in attracting FDI in the recombinant protein manufacturing space over the last 2 decades. There are now over 100 members representing a variety of different stakeholders including: government agencies, national funding agencies, MNCs, SMEs, HPRA, BPCI, NTMA, VCs, academics, equipment vendors, design/engineering houses and specialist recruiters.

 

The Forum is currently working on addressing what we believe Ireland needs to do to ensure we capitalise on the huge commercial and therapeutic opportunity that CGT&V represent. In Q1 2021 7 working groups were established to focus on specific areas we believe should be prioritised in order to ensure success:

  • Working Group 1: Development of a CGT & V manufacturing technical/capability ‘strengths-map’ for Ireland
  • Working Group 2: Understanding the big challenges facing CGT & V manufacturing
  • Working Group 3: Influencing Ireland investment/funding decision-making in CGT & V manufacturing
  • Working Group 4: Influencing European decision-making in CGT&V manufacturing
  • Working Group 5: CGT Education & Training
  • Working Group 6: CGTV indigenous start-ups and SMEs
  • Working Group 7: CGT Clinical Trials

 

Throughout 2021 these groups will generate recommendations and strategies that we hope will ultimately shape national policy and actions to ensure that the ecosystem:

  • Attracts FDI in the form of CGTV manufacturing activity (with an ambition to match the success in the recombinant protein space in recent decades)
  • Prioritises, supports and promotes indigenous innovation within the HEI and start-up sector
  • Provides relevant education and training offerings to ensure the development of an appropriately skilled workforce
  • Is an attractive location for supporting clinical trials in CGT&V

Please keep an eye on this website in the coming months which we hope to develop into a useful information portal for those interested in activities and expertise within Ireland in the CGT&V space.

For further information, please contact Prof. Niall Barron.

IMG_3360 Use2

NIBRT Research Office

Jennifer Byrne

Research Programme Manager

Jennifer.Byrne@nibrt.ie

Ciara McManus

Senior Research Contracts and IP Officer

Ciara.McManus@nibrt.ie

 

 

 

HRS4R

The award of the HRS4R identifies the research institutions and organizations supporting a favorable and boosted work environment.

 

The European Commission recognizes with the 'HR Excellence in Research Award' the institutions which make progress in aligning their human resources policies to the 40 principles of the Charter & Code, based on a customized action plan/HR strategy.

NIBRT Research Strategy 2021 -2026

Mission Statement: To conduct leading edge research, in collaboration with industry and academic partners, that focuses on advancing biopharmaceutical manufacturing, increases the pool of highly trained doctoral and postdoctoral level scientists, and supports the biopharmaceutical industry in Ireland and the world.

Expanded Vision Statement: NIBRT Research is a world leader in developing innovative technologies that advance biopharmaceutical manufacturing and a resource for the global biopharmaceutical industry. Inspired by the manufacturing challenges facing the industry, NIBRT Research makes transformative discoveries across multidisciplinary areas such as analytical science, cell and genetic engineering, informatics, and bioprocess engineering. These discoveries are utilized to advance the state-of-the-art in their fields and revolutionize the manufacturing of recombinant proteins, vaccines and cell and gene therapies. NIBRT Research engages postdoctoral scientists and graduate students in leading edge biopharmaceutical research, helping to inform and inspire the next generation of research leaders in industry and academia. NIBRT Research is comprised of eminent scientists supported by world-class facilities and dedicated support teams who actively pursue productive collaborations with academic and industrial scientists in Ireland and throughout the world. Thus, NIBRT will deliver outstanding biopharmaceutical manufacturing research built on effective collaboration and world-leading innovation.

Research_strategy

 

STRATEGIC AND ENABLING GOALS

Strategic Goal 1. To develop a world-leading Biologics Analysis Research Centre to address analytical challenges in manufacturing across current and emerging biopharma modalities.

Strategic Goal 2. To play a leadership role in developing Ireland as a preferred location for manufacturing advanced therapy medicinal products, including cell and gene therapies and vaccines.

Strategic Goal 3. To support the development of NIBRT intellectual property.

Strategic Goal 4. To educate and train world-leading postgraduate and postdoctoral scientists, developing future research leaders for NIBRT and for the biopharmaceutical industry.

Strategic Goal 5. To collaborate with Contract Analytical Services (NIBRT Services Limited; NSL) to support and expand the services offered, helping to build a thriving contract research business.

Enabling Goal 1. To communicate effectively with NIBRT Research’s stakeholders, internal and external, with the aim of influencing and developing NIBRT’s reputation for high-quality science.

Enabling Goal 2. To improve and expand NIBRT’s research infrastructure and research support measures to strengthen delivery of the NIBRT Research team and the mission.

Research Integrity NIBRT

NIBRT is committed to promoting the performance of research to the highest standards of
professionalism and rigour by its staff and students, and to the accuracy and integrity of the research
record in publications and elsewhere. NIBRT aims to promote integrity in research through good
example, training and open discussion of issues of research integrity.

Case Studies

Tyndall National Institute

Working with theTyndall National Institute Tyndall National Institute, Cork, and the National Institute for Bioprocessing…

View Case Study

Thermo Fisher Scientific

  NIBRT & ThermoFisher Scientific NIBRT are developing workflows using ThermoFisher Scientific technology including the…

View Case Study

Contact Us

Get in touch with NIBRT today to see how our Research Team can help you.